A tutorial on sensitivity analyses in clinical trials : the what, why, when and how by L. Thabane et al.
Thabane et al. BMC Medical Research Methodology 2013, 13:92
http://www.biomedcentral.com/1471-2288/13/92COMMENTARY Open AccessA tutorial on sensitivity analyses in clinical trials:
the what, why, when and how
Lehana Thabane1,2,3,4,5*, Lawrence Mbuagbaw1,4, Shiyuan Zhang1,4, Zainab Samaan1,6,7, Maura Marcucci1,4,
Chenglin Ye1,4, Marroon Thabane1,8, Lora Giangregorio9, Brittany Dennis1,4, Daisy Kosa1,4,10, Victoria Borg Debono1,4,
Rejane Dillenburg11, Vincent Fruci12, Monica Bawor13, Juneyoung Lee14, George Wells15 and Charles H Goldsmith1,4,16Abstract
Background: Sensitivity analyses play a crucial role in assessing the robustness of the findings or conclusions based
on primary analyses of data in clinical trials. They are a critical way to assess the impact, effect or influence of key
assumptions or variations—such as different methods of analysis, definitions of outcomes, protocol deviations,
missing data, and outliers—on the overall conclusions of a study.
The current paper is the second in a series of tutorial-type manuscripts intended to discuss and clarify aspects
related to key methodological issues in the design and analysis of clinical trials.
Discussion: In this paper we will provide a detailed exploration of the key aspects of sensitivity analyses including:
1) what sensitivity analyses are, why they are needed, and how often they are used in practice; 2) the different types
of sensitivity analyses that one can do, with examples from the literature; 3) some frequently asked questions about
sensitivity analyses; and 4) some suggestions on how to report the results of sensitivity analyses in clinical trials.
Summary: When reporting on a clinical trial, we recommend including planned or posthoc sensitivity analyses, the
corresponding rationale and results along with the discussion of the consequences of these analyses on the overall
findings of the study.
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The credibility or interpretation of the results of clinical
trials relies on the validity of the methods of analysis or
models used and their corresponding assumptions. An
astute researcher or reader may be less confident in the
findings of a study if they believe that the analysis or as-
sumptions made were not appropriate. For a primary
analysis of data from a prospective randomized con-
trolled trial (RCT), the key questions for investigators
(and for readers) include:
 How confident can I be about the results?
 Will the results change if I change the definition of
the outcome (e.g., using different cut-off points)?* Correspondence: ThabanL@mcmaster.ca
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reproduction in any medium, provided the origin Will the results change if I change the method of
analysis?
 Will the results change if we take missing data into
account? Will the method of handling missing data
lead to different conclusions?
 How much influence will minor protocol deviations
have on the conclusions?
 How will ignoring the serial correlation of
measurements within a patient impact the results?
 What if the data were assumed to have a non-
Normal distribution or there were outliers?
 Will the results change if one looks at subgroups of
patients?
 Will the results change if the full intervention is
received (i.e. degree of compliance)?td. This is an Open Access article distributed under the terms of the Creative
mons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
al work is properly cited.
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sensitivity analyses—testing the effect of these “changes”
on the observed results. If, after performing sensitivity
analyses the findings are consistent with those from the
primary analysis and would lead to similar conclusions
about treatment effect, the researcher is reassured that
the underlying factor(s) had little or no influence or
impact on the primary conclusions. In this situation, the
results or the conclusions are said to be “robust”.
The objectives of this paper are to provide an overview
of how to approach sensitivity analyses in clinical trials.
This is the second in a series of tutorial-type manu-
scripts intended to discuss and clarify aspects related to
some key methodological issues in the design and
analysis of clinical trials. The first was on pilot studies
[1]. We start by describing what sensitivity analysis is,
why it is needed and how often it is done in practice.
We then describe the different types of sensitivity ana-
lyses that one can do, with examples from the literature.
We also address some of the commonly asked questions
about sensitivity analysis and provide some guidance on
how to report sensitivity analyses.
Discussion
Sensitivity Analysis
What is a sensitivity analysis in clinical research?
Sensitivity Analysis (SA) is defined as “a method to de-
termine the robustness of an assessment by examining
the extent to which results are affected by changes in
methods, models, values of unmeasured variables, or
assumptions” with the aim of identifying “results that
are most dependent on questionable or unsupported as-
sumptions” [2]. It has also been defined as “a series of
analyses of a data set to assess whether altering any of
the assumptions made leads to different final interpreta-
tions or conclusions” [3]. Essentially, SA addresses the
“what-if-the-key-inputs-or-assumptions-changed”-type of
question. If we want to know whether the results change
when something about the way we approach the data
analysis changes, we can make the change in our analysis
approach and document the changes in the results or
conclusions. For more detailed coverage of SA, we refer
the reader to these references [4-7].
Why is sensitivity analysis necessary?
The design and analysis of clinical trials often rely on
assumptions that may have some effect, influence or im-
pact on the conclusions if they are not met. It is import-
ant to assess these effects through sensitivity analyses.
Consistency between the results of primary analysis and
the results of sensitivity analysis may strengthen the
conclusions or credibility of the findings. However, it is
important to note that the definition of consistency may
depend in part on the area of investigation, the outcomeof interest or even the implications of the findings or
results.
It is equally important to assess the robustness to
ensure appropriate interpretation of the results taking
into account the things that may have an impact on
them. Thus, it imperative for every analytic plan to have
some sensitivity analyses built into it.
The United States (US) Food and Drug Administration
(FDA) and the European Medicines Association (EMEA),
which offer guidance on Statistical Principles for Clinical
Trials, state that “it is important to evaluate the robustness
of the results and primary conclusions of the trial.” Ro-
bustness refers to “the sensitivity of the overall conclusions
to various limitations of the data, assumptions, and
analytic approaches to data analysis” [8]. The United
Kingdom (UK) National Institute of Health and Clinical
Excellence (NICE) also recommends the use of sensitivity
analysis in “exploring alternative scenarios and the uncer-
tainty in cost-effectiveness results” [9].
How often is sensitivity analysis reported in practice?
To evaluate how often sensitivity analyses are used in
medical and health research, we surveyed the January
2012 editions of major medical journals (British Medical
Journal, New England Journal of Medicine, the Lancet,
Journal of the American Medical Association and the
Canadian Medical Association Journal) and major health
economics journals (Pharmaco-economics, Medical Deci-
sion making, European Journal of Health Economics,
Health Economics and the Journal of Health Economics).
From every article that included some form of statistical
analyses, we evaluated: i) the percentage of published arti-
cles that reported results of some sensitivity analyses; and
ii) the types of sensitivity analyses that were performed.
Table 1 provides a summary of the findings. Overall, the
point prevalent use of sensitivity analyses is about 26.7%
(36/135) —which seems very low. A higher percentage of
papers published in health economics than in medical
journals (30.8% vs. 20.3%) reported some sensitivity ana-
lyses. Among the papers in medical journals, 18 (28.1%)
were RCTs, of which only 3 (16.6%) reported sensitivity
analyses. Assessing robustness of the findings to different
methods of analysis was the most common type of sensi-
tivity analysis reported in both types of journals. Therefore
despite their importance, sensitivity analyses are under-
used in practice. Further, sensitivity analyses are more
common in health economics research—for example in
conducting cost-effectiveness analyses, cost-utility analyses
or budget-impact analyses—than in other areas of health
or medical research.
Types of sensitivity analyses
In this section, we describe scenarios that may require
sensitivity analyses, and how one could use sensitivity
Table 1 Comparison of sensitivity analyses reported in





Number with statistical analysis 64$ 71
Number with sensitivity analysis (%) 13& (20.3) 22 (30.9)
Type of sensitivity analysis
• Methods of analysis 5 12
• Outcome definitions 4 1
• Distributional assumptions 1 0
• Key assumptions* 2 4
• Missing data 1 4
• Baseline imbalances 0 1
$Eighteen (18) of these were randomized controlled trials, of which only 3
reported sensitivity analyses.
&Of which 3 were randomized controlled trials and 10 were
observational studies.
*Assumptions related to the participants, interventions or outcomes that can
affect the results of the trial. For example, considering a second episode of
cancer as a relapse instead of a continuation of the first; in a cost-effectiveness
analysis, modifying the anticipated frequency of the intervention.
Table 2 Examples of common scenarios for sensitivity
analyses in clinical trials
Scenario Sensitivity analysis options
Outliers - Assess outlier by z-score or boxplot
- Perform analyses with and without outliers
Non-compliance or
protocol violation in RCTs
Perform
- Intention-to-treat analysis (as primary analysis)
- As-treated analysis
- Per-protocol analysis
Missing data - Analyze only complete cases
- Impute the missing data using single or
multiple imputation methods and redo
the analysis
Definitions of outcomes - Perform analyses on outcomes of
different cut-offs or definitions
Clustering or correlation - Compare the analysis that ignores
clustering with one primary method
chosen to account for clusteringand multi-center trials
- Compare the analysis that ignores
clustering with several methods of
accounting for clustering [10,11]
- Perform analysis with and without
adjusting for center
- Use different methods of adjusting for
center [12]
Competing risks in RCTs - Perform a survival analysis for each
event separately
- Use a proportional sub-distribution
hazard model (Fine & Grey approach)
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lyses or findings of RCTs. These are not meant to be
exhaustive, but rather to illustrate common situations
where sensitivity analyses might be useful to consider
(Table 2). In each case, we provide examples of actual
studies where sensitivity analyses were performed, and
the implications of these sensitivity analyses.- Fit one model by taking into account all
the competing risks together [13]
Baseline imbalance Perform:
- Analysis with and without adjustment for
baseline characteristics
- Analysis with different methods of
adjusting for baseline imbalance. e.g.
Multivariable regression vs. propensity
score method
Distributional assumptions Perform analyses under different
distributional assumptions
- Different distributions (e.g. Poisson vs.
Negative binomial)
- Parametric vs. non-parametric methods
- Classical vs. Bayesian methods
- Different prior distributionsImpact of outliers
An outlier is an observation that is numerically distant
from the rest of the data. It deviates markedly from the
rest of the sample from which it comes [14,15]. Outliers
are usually exceptional cases in a sample. The problem
with outliers is that they can deflate or inflate the mean
of a sample and therefore influence any estimates of
treatment effect or association that are derived from the
mean. To assess the potential impact of outliers, one
would first assess whether or not any observations
meet the definition of an outlier—using either a
boxplot or z-scores [16]. Second, one could perform a
sensitivity analysis with and without the outliers.
Examples:
 In a cost–utility analysis of a practice-based
osteopathy clinic for subacute spinal pain, Williams
et al. reported lower costs per quality of life year
ratios when they excluded outliers [17]. In other
words, there were certain participants in the trial
whose costs were very high, and were making the
average costs look higher than they probably were in
reality. The observed cost per quality of life year wasnot robust to the exclusion of outliers, and changed
when they were excluded.
 A primary analysis based on the intention-to-treat
principle showed no statistically significant
differences in reducing depression between a nurse-
led cognitive self-help intervention program
compared to standard care among 218 patients
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sensitivity analyses in this trial were performed by
excluding participants with high baseline levels of
depression (outliers) and showed a statistically
significant reduction in depression in the
intervention group compared to the control. This
implies that the results of the primary analysis were
affected by the presence of patients with baseline
high depression [18].
Impact of non-compliance or protocol deviations
In clinical trials some participants may not adhere to the
intervention they were allocated to receive or comply
with the scheduled treatment visits. Non-adherence or
non-compliance is a form of protocol deviation. Other
types of protocol deviations include switching between
intervention and control arms (i.e. treatment switching
or crossovers) [19,20], or not implementing the inter-
vention as prescribed (i.e. intervention fidelity) [21,22].
Protocol deviations are very common in interventional
research [23-25]. The potential impact of protocol devia-
tions is the dilution of the treatment effect [26,27].
Therefore, it is crucial to determine the robustness of
the results to the inclusion of data from participants
who deviate from the protocol. Typically, for RCTs the
primary analysis is based on an intention-to-treat (ITT)
principle—in which participants are analyzed according
to the arm to which they were randomized, irrespective
of whether they actually received the treatment or com-
pleted the prescribed regimen [28,29]. Two common
types of sensitivity analyses can be performed to assess
the robustness of the results to protocol deviations: 1)
per-protocol (PP) analysis—in which participants who
violate the protocol are excluded from the analysis [30];
and 2) as-treated (AT) analysis—in which participants
are analyzed according to the treatment they actually re-
ceived [30]. The PP analysis provides the ideal scenario
in which all the participants comply, and is more likely
to show an effect; whereas the ITT analysis provides a
“real life” scenario, in which some participants do not
comply. It is more conservative, and less likely to show
that the intervention is effective. For trials with repeated
measures, some protocol violations which lead to miss-
ing data can be dealt with alternatively. This is covered
in more detail in the next section.
Examples:
 A trial was designed to investigate the effects of an
electronic screening and brief intervention to change
risky drinking behaviour in university students. The
results of the ITT analysis (on all 2336 participants
who answered the follow-up survey) showed that
the intervention had no significant effect. However,
a sensitivity analysis based on the PP analysis(including only those with risky drinking at baseline
and who answered the follow-up survey; n = 408)
suggested a small beneficial effect on weekly alcohol
consumption [31]. A reader might be less confident
in the findings of the trial because of the
inconsistency between the ITT and PP analyses—the
ITT was not robust to sensitivity analyses. A
researcher might choose to explore differences in
the characteristics of the participants who were
included in the ITT versus the PP analyses.
 A study compared the long-term effects of surgical
versus non-surgical management of chronic back
pain. Both the ITT and AT analyses showed no
significant difference between the two management
strategies [32]. A reader would be more confident in
the findings because the ITT and AT analyses were
consistent—the ITT was robust to sensitivity
analyses.
Impact of missing data
Missing data are common in every research study. This
is a problem that can be broadly defined as “missing
some information on the phenomena in which we are
interested” [33]. Data can be missing for different reasons
including (1) non-response in surveys due to lack of inter-
est, lack of time, nonsensical responses, and coding errors
in data entry/transfer; (2) incompleteness of data in large
data registries due to missing appointments, not everyone
is captured in the database, and incomplete data; and (3)
missingness in prospective studies as a result of loss to
follow up, dropouts, non-adherence, missing doses, and
data entry errors.
The choice of how to deal with missing data would de-
pend on the mechanisms of missingness. In this regard,
data can be missing at random (MAR), missing not at
random (MNAR), or missing completely at random
(MCAR). When data are MAR, the missing data are
dependent on some other observed variables rather than
any unobserved one. For example, consider a trial to
investigate the effect of pre-pregnancy calcium supple-
mentation on hypertensive disorders in pregnancy. Miss-
ing data on the hypertensive disorders is dependent
(conditional) on being pregnant in the first place. When
data are MCAR, the cases with missing data may be
considered a random sample drawn from all the cases.
In other words, there is no “cause” of missingness. Con-
sider the example of a trial comparing a new cancer
treatment to standard treatment in which participants
are followed at 4, 8, 12 and 16 months. If a participant
misses the follow up at the 8th and 16th months and
these are unrelated to the outcome of interest, in this
case mortality, then this missing data is MCAR. Reasons
such as a clinic staff being ill or equipment failure are
often unrelated to the outcome of interest. However, the
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the reason data is missing may not be known and there-
fore it is difficult to determine if it is related to the out-
come of interest. When data are MNAR, missingness is
dependent on some unobserved data. For example, in the
case above, if the participant missed the 8th month
appointment because he was feeling worse or the 16th
month appointment because he was dead, the missingness
is dependent on the data not observed because the partici-
pant was absent. When data are MAR or MCAR, they are
often referred to as ignorable (provided the cause of MAR
is taken into account). MNAR on the other hand, is
nonignorable missingness. Ignoring the missingness in
such data leads to biased parameter estimates [34]. Ignor-
ing missing data in analyses can have implications on the
reliability, validity and generalizability of research findings.
The best way to deal with missing data is prevention,
by steps taken in the design and data collection stages,
some of which have been described by Little et al. [35].
But this is difficult to achieve in most cases. There are
two main approaches to handling missing data: i) ignore
them—and use complete case analysis; and ii) impute
them—using either single or multiple imputation tech-
niques. Imputation is one of the most commonly used
approaches to handling missing data. Examples of single
imputation methods include hot deck, cold deck
method, mean imputation, regression technique, last
observation carried forward (LOCF) and composite
methods—which uses a combination of the above
methods to impute missing values. Single imputation
methods often lead to biased estimates and under-
estimation of the true variability in the data. Multiple
imputation (MI) technique is currently the best available
method of dealing with missing data under the assump-
tion that data are missing at random (MAR) [33,36-38].
MI addresses the limitations of single imputation by
using multiple imputed datasets which yield unbiased
estimates, and also accounts for the within- and
between-dataset variability. Bayesian methods using
statistical models that assume a prior distribution for the
missing data can also be used to impute data [35].
It is important to note that ignoring missing data in
the analysis would be implicitly assuming that the data
are MCAR, an assumption that is often hard to verify
in reality.
There are some statistical approaches to dealing with
missing data that do not necessarily require formal imput-
ation methods. For example, in studies using continuous
outcomes, linear mixed models for repeated measures are
used for analyzing outcomes measured repeatedly over
time [39,40]. For categorical responses or count data, gen-
eralized estimating equations [GEE] and random-effects
generalized linear mixed models [GLMM] methods may
be used [41,42]. In these models it is assumed that missingdata are MAR. If this assumption is valid, then the
complete-case analysis by including predictors of missing
observations will provide consistent estimates of the
parameter.
The choice of whether to ignore or impute missing
data, and how to impute it, may affect the findings of
the trial. Although one approach (ignore or impute, and
if the latter, how to impute) should be made a priori, a
sensitivity analysis can be done with a different approach
to see how “robust” the primary analysis is to the chosen
method for handling missing data.
Examples:
 A 2011 paper reported the sensitivity analyses of
different strategies for imputing missing data in
cluster RCTs with a binary outcome using the
community hypertension assessment trial (CHAT)
as an example. They found that variance in the
treatment effect was underestimated when the
amount of missing data was large and the
imputation strategy did not take into account the
intra-cluster correlation. However, the effects of the
intervention under various methods of imputation
were similar. The CHAT intervention was not
superior to usual care [43].
 In a trial comparing methotrexate with to placebo in
the treatment of psoriatic arthritis, the authors
reported both an intention-to-treat analysis (using
multiple imputation techniques to account for
missing data) and a complete case analysis (ignoring
the missing data). The complete case analysis, which
is less conservative, showed some borderline
improvement in the primary outcome (psoriatic
arthritis response criteria), while the intention-to-treat
analysis did not [44]. A reader would be less confident
about the effects of methotrexate on psoriatic
arthritis, due to the discrepancy between the results
with imputed data (ITT) and the complete
case analysis.Impact of different definitions of outcomes (e.g. different
cut-off points for binary outcomes)
Often, an outcome is defined by achieving or not
achieving a certain level or threshold of a measure. For
example in a study measuring adherence rates to medi-
cation, levels of adherence can be dichotomized as
achieving or not achieving at least 80%, 85% or 90% of
pills taken. The choice of the level a participant has to
achieve can affect the outcome—it might be harder to
achieve 90% adherence than 80%. Therefore, a sensitiv-
ity analysis could be performed to see how redefining
the threshold changes the observed effect of a given
intervention.
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 In a trial comparing caspofungin to amphotericin B
for febrile neutropoenic patients, a sensitivity
analysis was conducted to investigate the impact of
different definitions of fever resolution as part of a
composite endpoint which included: resolution of
any baseline invasive fungal infection, no
breakthrough invasive fungal infection, survival, no
premature discontinuation of study drug, and fever
resolution for 48 hours during the period of
neutropenia. They found that response rates were
higher when less stringent fever resolution
definitions were used, especially in low-risk patients.
The modified definitions of fever resolution were: no
fever for 24 hours before the resolution of
neutropenia; no fever at the 7-day post-therapy
follow-up visit; and removal of fever resolution
completely from the composite endpoint. This
implies that the efficacy of both medications
depends somewhat on the definition of the
outcomes [45].
 In a phase II trial comparing minocycline and
creatinine to placebo for Parkinson’s disease, a
sensitivity analysis was conducted based on another
definition (threshold) for futility. In the primary
analysis a predetermined futility threshold was set at
30% reduction in mean change in Unified
Parkinson’s Disease Rating Scale (UPDRS) score,
derived from historical control data. If minocycline
or creatinine did not bring about at least a 30%
reduction in UPDRS score, they would be
considered as futile and no further testing will be
conducted. Based on the data derived from the
current control (placebo) group, a new threshold of
32.4% (more stringent) was used for the sensitivity
analysis. The findings from the primary analysis and
the sensitivity analysis both confirmed that that
neither creatine nor minocycline could be rejected
as futile and should both be tested in Phase III trials
[46]. A reader would be more confident of these
robust findings.
Impact of different methods of analysis to account for
clustering or correlation
Interventions can be administered to individuals, but
they can also be administered to clusters of individuals,
or naturally occurring groups. For example, one might
give an intervention to students in one class, and com-
pare their outcomes to students in another class – the
class is the cluster. Clusters can also be patients treated
by the same physician, physicians in the same practice
center or hospital, or participants living in the same
community. Likewise, in the same trial, participants may
be recruited from multiple sites or centers. Each of thesecenters will represent a cluster. Patients or elements
within a cluster often have some appreciable degree of
homogeneity as compared to patients between clusters.
In other words, members of the same cluster are more
likely to be similar to each other than they are to mem-
bers of another cluster, and this similarity may then be
reflected in the similarity or correlation measure, on the
outcome of interest.
There are several methods of accounting or adjusting
for similarities within clusters, or “clustering” in studies
where this phenomenon is expected or exists as part of
the design (e.g., in cluster randomization trials). There-
fore, in assessing the impact of clustering one can build
into the analytic plans two forms of sensitivity analyses:
i) analysis with and without taking clustering into
account—comparing the analysis that ignores clustering
(i.e. assumes that the data are independent) to one
primary method chosen to account for clustering; ii)
analysis that compares several methods of accounting
for clustering.
Correlated data may also occur in longitudinal studies
through repeat or multiple measurements from the same
patient, taken over time or based on multiple responses
in a single survey. Ignoring the potential correlation be-
tween several measurements from an individual can lead
to inaccurate conclusions [47].
Here are a few references to studies that compared the
outcomes that resulted when different methods were/
were not used to account for clustering. Noteworthy, is
the fact that the analytical approaches for cluster-RCTs
and multi-site RCTs are similar.
Examples:
 Ma et al. performed sensitivity analyses of different
methods of analysing cluster RCTs [48]. In this
paper they compared three cluster-level methods
(un-weighted linear regression, weighted linear
regression and random-effects meta-regression) to
six individual level analysis methods (standard
logistic regression, robust standard errors approach,
GEE, random effects meta-analytic approach,
random-effects logistic regression and Bayesian
random-effects regression). Using data from the
CHAT trial, in this analysis, all nine methods
provided similar results, re-enforcing the hypothesis
that the CHAT intervention was not superior to
usual care.
 Peters et al. conducted sensitivity analyses to
compare different methods—three cluster-level (un-
weighted regression of practice log odds, regression
of log odds weighted by their inverse variance and
random-effects meta-regression of log odds with
cluster as a random effect) and five individual-level
methods (standard logistic regression ignoring
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effects logistic regression and Bayesian random-
effects logistic regression.)—for analyzing cluster
randomized trials using an example involving a
factorial design [13]. In this analysis, they
demonstrated that the methods used in the analysis
of cluster randomized trials could give varying
results, with standard logistic regression ignoring
clustering being the least conservative.
 Cheng et al. used sensitivity analyses to compare
different methods (six models for clustered binary
outcomes and three models for clustered nominal
outcomes) of analysing correlated data in discrete
choice surveys [49]. The results were robust to
various statistical models, but showed more
variability in the presence of a larger cluster effect
(higher within-patient correlation).
 A trial evaluated the effects of lansoprazole on
gastro-esophageal reflux disease in children from 19
clinics with asthma. The primary analysis was based
on GEE to determine the effect of lansoprazole in
reducing asthma symptoms. Subsequently they
performed a sensitivity analysis by including the
study site as a covariate. Their finding that
lansoprazole did not significantly improve symptoms
was robust to this sensitivity analysis [50].
 In addition to comparing the performance of
different methods to estimate treatment effects on a
continuous outcome in simulated multicenter
randomized controlled trials [12], the authors used
data from the Computerization of Medical Practices
for the Enhancement of Therapeutic Effectiveness
(COMPETE) II [51] to assess the robustness of the
primary results (based on GEE to adjust for
clustering by provider of care) under different
methods of adjusting for clustering. The results,
which showed that a shared electronic decision
support system improved care and outcomes in
diabetic patients, were robust under different
methods of analysis.
Impact of competing risks in analysis of trials with
composite outcomes
A competing risk event happens in situations where
multiple events are likely to occur in a way that the
occurrence of one event may prevent other events from
being observed [48]. For example, in a trial using a com-
posite of death, myocardial infarction or stroke, if some-
one dies, they cannot experience a subsequent event, or
stroke or myocardial infarction—death can be a compet-
ing risk event. Similarly, death can be a competing risk
in trials of patients with malignant diseases where
thrombotic events are important. There are several
options for dealing with competing risks in survivalanalyses: (1) to perform a survival analysis for each event
separately, where the other competing event(s) is/are
treated as censored; the common representation of sur-
vival curves using the Kaplan-Meier estimator is in this
context replaced by the cumulative incidence function
(CIF) which offers a better interpretation of the inci-
dence curve for one risk, regardless of whether the com-
peting risks are independent; (2) to use a proportional
sub-distribution hazard model (Fine & Grey approach)
in which subjects that experience other competing
events are kept in the risk set for the event of interest (i.e.
as if they could later experience the event); (3) to fit one
model, rather than separate models, taking into account
all the competing risks together (Lunn-McNeill approach)
[13]. Therefore, the best approach to assessing the influ-
ence of a competing risk would be to plan for sensitivity
analysis that adjusts for the competing risk event.
Examples:
 A previously-reported trial compared low molecular
weight heparin (LMWH) with oral anticoagulant
therapy for the prevention of recurrent venous
thromboembolism (VTE) in patients with advanced
cancer, and a subsequent study presented sensitivity
analyses comparing the results from standard
survival analysis (Kaplan-Meier method) with those
from competing risk methods—namely, the
cumulative incidence function (CIF) and Gray's test
[52]. The results using both methods were similar.
This strengthened their confidence in the
conclusion that LMWH reduced the risk of
recurrent VTE.
 For patients at increased risk of end stage renal
disease (ESRD) but also of premature death not
related to ESRD, such as patients with diabetes or
with vascular disease, analyses considering the two
events as different outcomes may be misleading if
the possibility of dying before the development of
ESRD is not taken into account [49]. Different
studies performing sensitivity analyses demonstrated
that the results on predictors of ESRD and death for
any cause were dependent on whether the
competing risks were taken into account or not
[53,54], and on which competing risk method was
used [55]. These studies further highlight the need
for a sensitivity analysis of competing risks when
they are present in trials.
Impact of baseline imbalance in RCTs
In RCTs, randomization is used to balance the expected
distribution of the baseline or prognostic characteristics of
the patients in all treatment arms. Therefore the primary
analysis is typically based on ITT approach unadjusted for
baseline characteristics. However, some residual imbalance
Thabane et al. BMC Medical Research Methodology 2013, 13:92 Page 8 of 12
http://www.biomedcentral.com/1471-2288/13/92can still occur by chance. One can perform a sensitivity
analysis by using a multivariable analysis to adjust for
hypothesized residual baseline imbalances to assess their
impact on effect estimates.
Examples:
 A paper presented a simulation study where the risk
of the outcome, effect of the treatment, power and
prevalence of the prognostic factors, and sample
size were all varied to evaluate their effects on the
treatment estimates. Logistic regression models
were compared with and without adjustment for
the prognostic factors. The study concluded that
the probability of prognostic imbalance in small
trials could be substantial. Also, covariate
adjustment improved estimation accuracy and
statistical power [56].
 In a trial testing the effectiveness of enhanced
communication therapy for aphasia and dysarthria
after stroke, the authors conducted a sensitivity
analysis to adjust for baseline imbalances. Both
primary and sensitivity analysis showed that
enhanced communication therapy had no additional
benefit [57].
Impact of distributional assumptions
Most statistical analyses rely on distributional assumptions
for observed data (e.g. Normal distribution for continuous
outcomes, Poisson distribution for count data, or binomial
distribution for binary outcome data). It is important not
only to test for goodness-of-fit for these distributions, but
to also plan for sensitivity analyses using other suitable
distributions. For example, for continuous data, one can
redo the analysis assuming a Student-T distribution—
which is symmetric, bell-shaped distribution like the Nor-
mal distribution, but with thicker tails; for count data,
once can use the Negative-binomial distribution—which
would be useful to assess the robustness of the results if
over-dispersion is accounted for [52]. Bayesian analyses
routinely include sensitivity analyses to assess the robust-
ness of findings under different models for the data and
prior distributions [58]. Analyses based on parametric
methods—which often rely on strong distributional as-
sumptions—may also need to be evaluated for robustness
using non-parametric methods. The latter often make less
stringent distributional assumptions. However, it is essen-
tial to note that in general non-parametric methods are
less efficient (i.e. have less statistical power) than their
parametric counter-parts if the data are Normally
distributed.
Examples:
 Ma et al. performed sensitivity analyses based on
Bayesian and classical methods for analysing clusterRCTs with a binary outcome in the CHAT trial. The
similarities in the results after using the different
methods confirmed the results of the primary
analysis: the CHAT intervention was not superior to
usual care [10].
 A negative binomial regression model was used [52]
to analyze discrete outcome data from a clinical trial
designed to evaluate the effectiveness of a pre-
habilitation program in preventing functional
decline among physically frail, community-living
older persons. The negative binomial model
provided an improved fit to the data than the
Poisson regression model. The negative binomial
model provides an alternative approach for
analyzing discrete data where over-dispersion is a
problem [59].
Commonly asked questions about sensitivity analyses
 Q: Do I need to adjust the overall level of
significance for performing sensitivity analyses?
A: No. Sensitivity analysis is typically a re-analysis of
either the same outcome using different approaches, or
different definitions of the outcome—with the primary
goal of assessing how these changes impact the conclu-
sions. Essentially everything else including the criterion
for statistical significance needs to be kept constant so
that we can assess whether any impact is attributable to
underlying sensitivity analyses.
 Q: Do I have to report all the results of the
sensitivity analyses?
A: Yes, especially if the results are different or lead to
different a conclusion from the original results—whose
sensitivity was being assessed. However, if the results re-
main robust (i.e. unchanged), then a brief statement to
this effect may suffice.
 Q: Can I perform sensitivity analyses posthoc?
A: It is desirable to document all planned analyses in-
cluding sensitivity analyses in the protocol a priori. Some-
times, one cannot anticipate all the challenges that can
occur during the conduct of a study that may require
additional sensitivity analyses. In that case, one needs to
incorporate the anticipated sensitivity analyses in the stat-
istical analysis plan (SAP), which needs to be completed
before analyzing the data. Clear rationale is needed for
every sensitivity analysis. This may also occur posthoc.
 Q: How do I choose between the results of different
sensitivity analyses? (i.e. which results are the best?)
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“best” results. Rather, the aim is to assess the robust-
ness or consistency of the results under different
methods, subgroups, definitions, assumptions and so
on. The assessment of robustness is often based on the
magnitude, direction or statistical significance of the
estimates. You cannot use the sensitivity analysis to
choose an alternate conclusion to your study. Rather,
you can state the conclusion based on your primary
analysis, and present your sensitivity analysis as an
example of how confident you are that it represents
the truth. If the sensitivity analysis suggests that the
primary analysis is not robust, it may point to the need
for future research that might address the source of
the inconsistency. Your study cannot answer the ques-
tion which results are best? To answer the question of
which method is best and under what conditions, simu-
lation studies comparing the different approaches on
the basis of bias, precision, coverage or efficiency may
be necessary.
 Q: When should one perform sensitivity analysis?
A: The default position should be to plan for sensitiv-
ity analysis in every clinical trial. Thus, all studies need
to include some sensitivity analysis to check the robust-
ness of the primary findings. All statistical methods used
to analyze data from clinical trials rely on assumptions—
which need to either be tested whenever possible, with
the results assessed for robustness through some sensi-
tivity analyses. Similarly, missing data or protocol devia-
tions are common occurrences in many trials and their
impact on inferences needs to be assessed.
 Q: How many sensitivity analyses can one perform
for a single primary analysis?
A: The number is not an important factor in deter-
mining what sensitivity analyses to perform. The most
important factor is the rationale for doing any sensitiv-
ity analysis. Understanding the nature of the data, and
having some content expertise are useful in determining
which and how many sensitivity analyses to perform.
For example, varying the ways of dealing with missing
data is unlikely to change the results if 1% of data are
missing. Likewise, understanding the distribution of cer-
tain variables can help to determine which cut points
would be relevant. Typically, it is advisable to limit sen-
sitivity analyses to the primary outcome. Conducting
multiple sensitivity analysis on all outcomes is often
neither practical, nor necessary.
 Q: How many factors can I vary in performing
sensitivity analyses?A: Ideally, one can study the impact of all key ele-
ments using a factorial design—which would allow the
assessment of the impact of individual and joint factors.
Alternatively, one can vary one factor at a time to be
able to assess whether the factor is responsible for the
resulting impact (if any). For example, in a sensitivity
analysis to assess the impact of the Normality assump-
tion (analysis assuming Normality e.g. T-test vs. analysis
without assuming Normality e.g. Based on a sign test)
and outlier (analysis with and without outlier), this can
be achieved through 2x2 factorial design.
 Q: What is the difference between secondary
analyses and sensitivity analyses?
A: Secondary analyses are typically analyses of second-
ary outcomes. Like primary analyses which deal with pri-
mary outcome(s), such analyses need to be documented
in the protocol or SAP. In most studies such analyses
are exploratory—because most studies are not powered
for secondary outcomes. They serve to provide support
that the effects reported in the primary outcome are
consistent with underlying biology. They are different
from sensitivity analyses as described above.
 Q: What is the difference between subgroup
analyses and sensitivity analyses?
A: Subgroup analyses are intended to assess whether
the effect is similar across specified groups of patients or
modified by certain patient characteristics [60]. If the
primary results are statistically significant, subgroup ana-
lyses are intended to assess whether the observed effect
is consistent across the underlying patient subgroups—
which may be viewed as some form of sensitivity ana-
lysis. In general, for subgroup analyses one is interested
in the results for each subgroup, whereas in subgroup
“sensitivity” analyses, one is interested in the similarity of
results across subgroups (ie. robustness across subgroups).
Typically subgroup analyses require specification of
the subgroup hypothesis and rationale, and performed
through inclusion of an interaction term (i.e. of the sub-
group variable x main exposure variable) in the regression
model. They may also require adjustment for alpha—the
overall level of significance. Furthermore, most studies are
not usually powered for subgroup analyses.
Conclusion
Reporting of sensitivity analyses
There has been considerable attention paid to enhancing
the transparency of reporting of clinical trials. This has
led to several reporting guidelines, starting with the
CONSORT Statement [61] in 1996 and its extensions
[www.equator-network.org]. Not one of these guidelines
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reported. On the other hand, there is some guidance on
how sensitivity analyses need to be reported in economic
analyses [62]—which may partly explain the differential
rates of reporting of sensitivity analyses shown in Table 1.
We strongly encourage some modifications of all reporting
guidelines to include items on sensitivity analyses—as a
way to enhance their use and reporting. The proposed
reporting changes can be as follows:
 In Methods Section: Report the planned or posthoc
sensitivity analyses and rationale for each.
 In Results Section: Report whether or not the results
of the sensitivity analyses or conclusions are similar
to those based on primary analysis. If similar, just
state that the results or conclusions remain robust.
If different, report the results of the sensitivity
analyses along with the primary results.
 In Discussion Section: Discuss the key limitations
and implications of the results of the sensitivity
analyses on the conclusions or findings. This can be
done by describing what changes the sensitivity
analyses bring to the interpretation of the data, and
whether the sensitivity analyses are more stringent
or more relaxed than the primary analysis.
Some concluding remarks
Sensitivity analyses play an important role is checking
the robustness of the conclusions from clinical trials.
They are important in interpreting or establishing the
credibility of the findings. If the results remain robust
under different assumptions, methods or scenarios, this
can strengthen their credibility. The results of our brief
survey of January 2012 editions of major medical and
health economics journals that show that their use is
very low. We recommend that some sensitivity analysis
should be the default plan in statistical or economic ana-
lyses of any clinical trial. Investigators need to identify
any key assumptions, variations, or methods that may
impact or influence the findings, and plan to conduct
some sensitivity analyses as part of their analytic strat-
egy. The final report must include the documentation of
the planned or posthoc sensitivity analyses, rationale,
corresponding results and a discussion of their conse-
quences or repercussions on the overall findings.
Abbreviations
SA: Sensitivity analysis; US: United States; FDA: Food and Drug
Administration; EMEA: European Medicines Association; UK: United Kingdom;
NICE: National Institute of Health and Clinical Excellence; RCT: Randomized
controlled trial; ITT: Intention-to-treat; PP: Per-protocol; AT: As-treated;
LOCF: Last observation carried forward; MI: Multiple imputation;
MAR: Missing at random; GEE: Generalized estimating equations;
GLMM: Generalized linear mixed models; CHAT: Community hypertension
assessment trial; PSA: Prostate specific antigen; CIF: Cumulative incidence
function; ESRD: End stage renal disease; IV: Instrumental variable;ANCOVA: Analysis of covariance; SAP: Statistical analysis plan;
CONSORT: Consolidated Standards of Reporting Trials.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LT conceived the idea and drafted the outline and paper. GW, CHG and MT
commented on the idea and draft outline. LM and SZ performed literature
search and data abstraction. ZS, LG and CY edited and formatted the
manuscript. MM, BD, DK, VBD, RD, VF, MB, JL reviewed and revised draft
versions of the manuscript. All authors reviewed several draft versions of the
manuscript and approved the final manuscript.
Acknowledgements
This work was supported in part by funds from the CANNeCTIN programme.
Author details
1Department of Clinical Epidemiology and Biostatistics, McMaster University,
Hamilton, ON, Canada. 2Departments of Pediatrics and Anesthesia, McMaster
University, Hamilton, ON, Canada. 3Center for Evaluation of Medicine, St
Joseph’s Healthcare Hamilton, Hamilton, ON, Canada. 4Biostatistics Unit,
Father Sean O’Sullivan Research Center, St Joseph’s Healthcare Hamilton,
Hamilton, ON, Canada. 5Population Health Research Institute, Hamilton
Health Sciences, Hamilton, ON, Canada. 6Department of Psychiatry and
Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada.
7Population Genomics Program, McMaster University, Hamilton, ON, Canada.
8GSK, Mississauga, ON, Canada. 9Department of Kinesiology, University of
Waterloo, Waterloo, ON, Canada. 10Department of Nephrology, Toronto
General Hospital, Toronto, ON, Canada. 11Department of Pediatrics, McMaster
University, Hamilton, ON, Canada. 12Michael G. DeGroote School of Medicine,
McMaster University, Hamilton, ON, Canada. 13McMaster Integrative
Neuroscience Discovery & Study (MiNDS) Program, McMaster University,
Hamilton, ON, Canada. 14Department of Biostatistics, Korea University, Seoul,
Korea. 15Department of Clinical Epidemiology, University of Ottawa, Ottawa,
ON, Canada. 16Faculty of Health Sciences, Simon Fraser University, Burnaby,
BC, Canada.
Received: 11 December 2012 Accepted: 10 July 2013
Published: 16 July 2013
References
1. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M,
Giangregorio L, Goldsmith CH: A tutorial on pilot studies: the what, why
and how. BMC Med Res Methodol 2010, 10:1.
2. Schneeweiss S: Sensitivity analysis and external adjustment for
unmeasured confounders in epidemiologic database studies of
therapeutics. Pharmacoepidemiol Drug Saf 2006, 15(5):291–303.
3. Viel JF, Pobel D, Carre A: Incidence of leukaemia in young people around
the La Hague nuclear waste reprocessing plant: a sensitivity analysis.
Stat Med 1995, 14(21–22):2459–2472.
4. Goldsmith CH, Gafni A, Drummond MF, Torrance GW, Stoddart GL: Sensitivity
Analysis and Experimental Design: The Case of Economic Evaluation of Health
Care Programmes. Proceedings of the Third Canadian Conference on Health
Economics 1986. Winnipeg MB: The University of Manitoba Press; 1987.
5. Saltelli A, Tarantola S, Campolongo F, Ratto M: Sensitivity Analysis in Practice:
A Guide to Assessing Scientific Models. New York, NY: Willey; 2004.
6. Saltelli A, Ratto M, Andres T, Campolongo F, Cariboni J, Gatelli D, Saisana M,
Tarantola S: Global Sensitivity Analysis: The Primer. New York, NY: Wiley-
Interscience; 2008.
7. Hunink MGM, Glasziou PP, Siegel JE, Weeks JC, Pliskin JS, Elstein AS,
Weinstein MC: Decision Making in Health and Medicine: Integrating Evidence
and Values. Cambridge: Cambridge University Press; 2001.
8. USFDA: International Conference on Harmonisation; Guidance on
Statistical Principles for Clinical Trials. Guideline E9. Statistical principles
for clinical trials. Federal Register, 16 September 1998, Vol. 63, No. 179,
p. 49583. [http://www.fda.gov/downloads/RegulatoryInformation/
Guidances/UCM129505.pdf]
9. NICE: Guide to the methods of technology appraisal. [http://www.nice.
org.uk/media/b52/a7/tamethodsguideupdatedjune2008.pdf]
Thabane et al. BMC Medical Research Methodology 2013, 13:92 Page 11 of 12
http://www.biomedcentral.com/1471-2288/13/9210. Ma J, Thabane L, Kaczorowski J, Chambers L, Dolovich L, Karwalajtys T,
Levitt C: Comparison of Bayesian and classical methods in the analysis
of cluster randomized controlled trials with a binary outcome: the
Community Hypertension Assessment Trial (CHAT). BMC Med Res
Methodol 2009, 9:37.
11. Peters TJ, Richards SH, Bankhead CR, Ades AE, Sterne JA: Comparison of
methods for analysing cluster randomized trials: an example involving a
factorial design. Int J Epidemiol 2003, 32(5):840–846.
12. Chu R, Thabane L, Ma J, Holbrook A, Pullenayegum E, Devereaux PJ:
Comparing methods to estimate treatment effects on a continuous
outcome in multicentre randomized controlled trials: a simulation study.
BMC Med Res Methodol 2011, 11:21.
13. Kleinbaum DG, Klein M: Survival Analysis – A-Self Learning Text. 3rd edition.
Springer; 2012.
14. Barnett V, Lewis T: Outliers in Statistical Data. 3rd edition. John Wiley & Sons;
1994.
15. Grubbs FE: Procedures for detecting outlying observations in samples.
Technometrics 1969, 11:1–21.
16. Thabane L, Akhtar-Danesh N: Guidelines for reporting descriptive statistics
in health research. Nurse Res 2008, 15(2):72–81.
17. Williams NH, Edwards RT, Linck P, Muntz R, Hibbs R, Wilkinson C, Russell I,
Russell D, Hounsome B: Cost-utility analysis of osteopathy in primary care:
results from a pragmatic randomized controlled trial. Fam Pract 2004,
21(6):643–650.
18. Zetta S, Smith K, Jones M, Allcoat P, Sullivan F: Evaluating the Angina Plan
in Patients Admitted to Hospital with Angina: A Randomized Controlled
Trial. Cardiovascular Therapeutics 2011, 29(2):112–124.
19. Morden JP, Lambert PC, Latimer N, Abrams KR, Wailoo AJ: Assessing
methods for dealing with treatment switching in randomised controlled
trials: a simulation study. BMC Med Res Methodol 2011, 11:4.
20. White IR, Walker S, Babiker AG, Darbyshire JH: Impact of treatment changes
on the interpretation of the Concorde trial. AIDS 1997, 11(8):999–1006.
21. Borrelli B: The assessment, monitoring, and enhancement of treatment
fidelity in public health clinical trials. J Public Health Dent 2011,
71(Suppl 1):S52–S63.
22. Lawton J, Jenkins N, Darbyshire JL, Holman RR, Farmer AJ, Hallowell N:
Challenges of maintaining research protocol fidelity in a clinical care
setting: a qualitative study of the experiences and views of patients and
staff participating in a randomized controlled trial. Trials 2011, 12:108.
23. Ye C, Giangregorio L, Holbrook A, Pullenayegum E, Goldsmith CH, Thabane
L: Data withdrawal in randomized controlled trials: Defining the problem
and proposing solutions: a commentary. Contemp Clin Trials 2011,
32(3):318–322.
24. Horwitz RI, Horwitz SM: Adherence to treatment and health outcomes.
Arch Intern Med 1993, 153(16):1863–1868.
25. Peduzzi P, Wittes J, Detre K, Holford T: Analysis as-randomized and the
problem of non-adherence: an example from the Veterans Affairs
Randomized Trial of Coronary Artery Bypass Surgery. Stat Med 1993,
12(13):1185–1195.
26. Montori VM, Guyatt GH: Intention-to-treat principle. CMAJ 2001,
165(10):1339–1341.
27. Gibaldi M, Sullivan S: Intention-to-treat analysis in randomized trials: who
gets counted? J Clin Pharmacol 1997, 37(8):667–672.
28. Porta M: A dictionary of epidemiology. 5th edition. Oxford: Oxford University
Press, Inc; 2008.
29. Everitt B: Medical statistics from A to Z. 2nd edition. Cambridge: Cambridge
University Press; 2006.
30. Sainani KL: Making sense of intention-to-treat. PM R 2010, 2(3):209–213.
31. Bendtsen P, McCambridge J, Bendtsen M, Karlsson N, Nilsen P: Effectiveness of
a proactive mail-based alcohol internet intervention for university students:
dismantling the assessment and feedback components in a randomized
controlled trial. J Med Internet Res 2012, 14(5):e142.
32. Brox JI, Nygaard OP, Holm I, Keller A, Ingebrigtsen T, Reikeras O: Four-year
follow-up of surgical versus non-surgical therapy for chronic low back
pain. Ann Rheum Dis 2010, 69(9):1643–1648.
33. McKnight PE, McKnight KM, Sidani S, Figueredo AJ: Missing Data: A Gentle
Introduction. New York, NY: Guilford; 2007.
34. Graham JW: Missing data analysis: making it work in the real world.
Annu Rev Psychol 2009, 60:549–576.
35. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT,
Frangakis C, Hogan JW, Molenberghs G, Murphy SA, et al: The Preventionand Treatment of Missing Data in Clinical Trials. New England Journal of
Medicine 2012, 367(14):1355–1360.
36. Little RJA, Rubin DB: Statistical Analysis with Missing Data. 2nd edition. New
York NY: Wiley; 2002.
37. Rubin DB: Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons,
Inc: New York NY; 1987.
38. Schafer JL: Analysis of Incomplete Multivariate Data. New York: Chapman and
Hall; 1997.
39. Son H, Friedmann E, Thomas SA: Application of pattern mixture models to
address missing data in longitudinal data analysis using SPSS.
Nursing research 2012, 61(3):195–203.
40. Peters SA, Bots ML, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR 3rd,
O'Leary DH, Evans GW, Raichlen JS, Moons KG, et al: Multiple imputation of
missing repeated outcome measurements did not add to linear mixed-
effects models. J Clin Epidemiol 2012, 65(6):686–695.
41. Zhang H, Paik MC: Handling missing responses in generalized linear
mixed model without specifying missing mechanism. J Biopharm Stat
2009, 19(6):1001–1017.
42. Chen HY, Gao S: Estimation of average treatment effect with
incompletely observed longitudinal data: application to a smoking
cessation study. Statistics in medicine 2009, 28(19):2451–2472.
43. Ma J, Akhtar-Danesh N, Dolovich L, Thabane L: Imputation strategies for
missing binary outcomes in cluster randomized trials. BMC Med Res
Methodol 2011, 11:18.
44. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ,
Mulherin DM, Kitas GD, Chakravarty K, Tom BD, et al: A randomized
placebo-controlled trial of methotrexate in psoriatic arthritis.
Rheumatology (Oxford) 2012, 51(8):1368–1377.
45. de Pauw BE, Sable CA, Walsh TJ, Lupinacci RJ, Bourque MR, Wise BA,
Nguyen BY, DiNubile MJ, Teppler H: Impact of alternate definitions of
fever resolution on the composite endpoint in clinical trials of empirical
antifungal therapy for neutropenic patients with persistent fever:
analysis of results from the Caspofungin Empirical Therapy Study.
Transpl Infect Dis 2006, 8(1):31–37.
46. A randomized, double-blind, futility clinical trial of creatine and
minocycline in early Parkinson disease. Neurology 2006, 66(5)):664–671.
47. Song P-K: Correlated Data Analysis: Modeling, Analytics and Applications. New
York, NY: Springer Verlag; 2007.
48. Pintilie M: Competing Risks: A Practical Perspective. New York, NY: John Wiley;
2006.
49. Tai BC, Grundy R, Machin D: On the importance of accounting for
competing risks in pediatric brain cancer: II. Regression modeling and
sample size. Int J Radiat Oncol Biol Phys 2011, 79(4):1139–1146.
50. Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima
JJ, Mastronarde JG, Sockrider MM, et al: Lansoprazole for children with
poorly controlled asthma: a randomized controlled trial. JAMA 2012,
307(4):373–381.
51. Holbrook A, Thabane L, Keshavjee K, Dolovich L, Bernstein B, Chan D,
Troyan S, Foster G, Gerstein H: Individualized electronic decision support
and reminders to improve diabetes care in the community: COMPETE II
randomized trial. CMAJ: Canadian Medical Association journal = journal de
l’Association medicale canadienne 2009, 181(1–2):37–44.
52. Hilbe JM: Negative Binomial Regression. 2nd edition. Cambridge: Cambridge
University Press; 2011.
53. Forsblom C, Harjutsalo V, Thorn LM, Waden J, Tolonen N, Saraheimo M,
Gordin D, Moran JL, Thomas MC, Groop PH: Competing-risk analysis of
ESRD and death among patients with type 1 diabetes and
macroalbuminuria. J Am Soc Nephrol 2011, 22(3):537–544.
54. Grams ME, Coresh J, Segev DL, Kucirka LM, Tighiouart H, Sarnak MJ:
Vascular disease, ESRD, and death: interpreting competing risk analyses.
Clin J Am Soc Nephrol 2012, 7(10):1606–1614.
55. Lim HJ, Zhang X, Dyck R, Osgood N: Methods of competing risks analysis
of end-stage renal disease and mortality among people with diabetes.
BMC Med Res Methodol 2010, 10:97.
56. Chu R, Walter SD, Guyatt G, Devereaux PJ, Walsh M, Thorlund K, Thabane L:
Assessment and implication of prognostic imbalance in randomized
controlled trials with a binary outcome–a simulation study. PLoS One
2012, 7(5):e36677.
57. Bowen A, Hesketh A, Patchick E, Young A, Davies L, Vail A, Long AF,
Watkins C, Wilkinson M, Pearl G, et al: Effectiveness of enhanced
communication therapy in the first four months after stroke for
Thabane et al. BMC Medical Research Methodology 2013, 13:92 Page 12 of 12
http://www.biomedcentral.com/1471-2288/13/92aphasia and dysarthria: a randomised controlled trial. BMJ 2012,
345:e4407.
58. Spiegelhalter DJ, Best NG, Lunn D, Thomas A: Bayesian Analysis using BUGS:
A Practical Introduction. New York, NY: Chapman and Hall; 2009.
59. Byers AL, Allore H, Gill TM, Peduzzi PN: Application of negative binomial
modeling for discrete outcomes: a case study in aging research. J Clin
Epidemiol 2003, 56(6):559–564.
60. Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of
treatment effects in subgroups of patients in randomized clinical trials.
JAMA: the journal of the American Medical Association 1991, 266(1):93–98.
61. Altman DG: Better reporting of randomised controlled trials: the
CONSORT statement. BMJ 1996, 313(7057):570–571.
62. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M,
Orlewska E, Watkins J, Trueman P: Principles of good practice for budget
impact analysis: report of the ISPOR Task Force on good research
practices–budget impact analysis. Value Health 2007, 10(5):336–347.
doi:10.1186/1471-2288-13-92
Cite this article as: Thabane et al.: A tutorial on sensitivity analyses in
clinical trials: the what, why, when and how. BMC Medical Research
Methodology 2013 13:92.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
